Randomized clinical trial to assess the efficacy of Suprachoroidal Triamcinolone Acetate injection in Non-infectious Uveitis

Uveitis is a group of intraocular inflammatory disorders affecting the uveal tract and surrounding tissues and is responsible for up to 15% of all cases of complete blindness in the developed world. It can be broadly classified as infectious and non-infectious uveitis (NIU). Each type is further classified based on anatomical location. Anterior uveitis is the most common entity comprising around 45%, followed by panuveitis (25%), while intermediate & posterior uveitis constitutes 15% of all cases.

Treatment of posterior uveitis is difficult as delivering efficacious levels of therapeutic agents is challenging and can lead to visual morbidity. Control of inflammation, preventing sight-threatening complications and minimizing recurrences are the main therapeutic goals. The most common complication of chronic NIU is cystoid macular edema (CME) leading to vision impairment in one-third of all uveitis patients, followed by choroidal neovascularization (CNV). Macular edema may persist even after inflammation is controlled; therefore, interventions should aim to resolve both inflammation and macular edema.

Present study is designed to study the role of triamcinolone acetonide injection in suprachoroidal space in different types of non-infectious uveitis for safety, efficacy, early recovery and prevention of relapse